secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2026-09-14T13:29:43+00:00
Accession:  0001493152-26-042508
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Biofrontera's Ameluz PDT for superficial basal cell carcinoma; launch expected Q4 2026–Q1 2027
--------------------------------------------------------------------------------

- FDA approved sNDA for Ameluz (aminolevulinic acid) topical gel 10% + BF-RhodoLED lamp for sBCC in adults; first US PDT approved for skin cancer.
- Phase 3 trial (187 adults): composite complete response 66% (95/145) with Ameluz PDT vs 5% (2/42) placebo; histological clearance 76% vs 19%.
- Estimated US market: 540,000–720,000 sBCC cases/yr (approx. 15–20% of 3.6M BCC cases); existing AK indication retained.
- Commercial launch of sBCC indication planned late Q4 2026 through Q1 2027 using existing commercial organization and installed lamp base.
- CEO Hermann Luebbert calls approval a defining milestone; expands addressable market and strengthens PDT platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/0001493152-26-042508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-042508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer